| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.043 | 0.8 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | -0.1 | 0.8 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.0084 | 0.8 |